ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
AI-based fluid quantification in neovascular age-related macular degeneration and diabetic macular edema treated with faricimab - a real-life study.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo assess faricimab treatment in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) with artificial intelligence-based fluid quantification on spectral-domain optical coherence tomography (SD-OCT).
methodsRetrospective patients with nAMD and DME; treatment-naïve, or on another intravitreal medication (switchers), loaded with 4 monthly intravitreal faricimab. SD-OCT (Heidelberg Engineering) at baseline and 16 weeks, then processed using the Fluid Monitor® (RetInSight). Sum of fluid volumes in the central 1 mm (pigment epithelial detachment, subretinal fluid, and intraretinal fluid) was computed (SF) and correlated with central subfield thickness (CST).
resultsThirty-four nAMD (25 switchers) and 21 DME (20 switchers) eyes were included. SF (nL) was 126.68 ± 17.24 and 37.84 ± 8.31 at baseline reduced to 80.78 ± 15.56 (p < 0.0001) and 15.28 ± 4.94 (p < 0.0001) for nAMD and DME, respectively. CST (µm) reduced from 405.12 ± 24.95 and 354.97 ± 15.89 to 320.33 ± 19.80 (p = 0.0001) and 302.41 ± 11.55 (p < 0.0001) in nAMD and DME, respectively. Mean intraindividual change between baseline and 16 weeks was larger using SF than with CST for nAMD (36.5% and 17.6%, respectively) and for DME (56.2% and 13.1%, respectively). A similar pattern was observed for each retinal compartment.
conclusionWhen loaded with faricimab, total fluid decreased by 37% in nAMD and 56% in DME. Fluid volumetry appears more sensitive for retinal fluid. TRANSLATIONAL RELEVANCE: When AI-fluid volumetry is applied real-world nAMD and DME cases, then fluid volume offers a more sensitive and quantifiable measure of disease activity than CST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.